Zimbabwe has turned down a substantial US healthcare agreement valued at $367m (£272m) spanning five years because of Washington's insistence on sensitive biological samples.
The decision became public following a internal memorandum from December was disclosed, revealing that President Emmerson Mnangagwa believed the arrangement was "lopsided".
A government representative later stated that the US was demanding access to genetic material for scientific study and commercial gain while was not willing to share the resulting advantages from future medical innovations.
"We must now begin the challenging and unfortunate process of scaling back our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy noted the United States had provided over $1.9bn for health programmes to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has appealed for continued dialogue to secure a deal acceptable to all parties so the country's vital HIV treatment initiative can proceed.
Broader Background
This development comes after a similar case in neighbouring Kenya, where a court halted a related health funding agreement after legal challenges were filed about the safety of citizens' health data.
Since resuming the presidency recently, US President Donald Trump has drastically cut overseas assistance and shut down the key foreign aid agency.
USAID had administered aid for the American government, but Trump stated its expenditure was "inefficient" and his government was pursuing direct bilateral agreements to enhance transparency and accountability.
As per statements, 16 nations in Africa have so far agreed to similar health pacts, representing over $18.3bn in committed funds.
Details of the Rejected Agreement
This assistance for Zimbabwe would have funded "combating HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We believe this partnership might have yielded immense advantages for the people of Zimbabwe, particularly the 1.2 million currently receiving antiretroviral therapy through US-supported initiatives," the Ambassador added.
However, government spokesperson Nick Mangwana said the arrangement was "unfair".
"Our nation was requested to provide its genetic material and health information indefinitely, with no equivalent assurance of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that might be developed from that shared data," Mangwana explained.
"Effectively, our country would provide the basic resources for scientific discovery with no certainty that the resulting innovations would be accessible to our population should a future health crisis arise."
National Interest and Global Health
He also pointed out that the US's withdrawal from the global health body and its push of bilateral deals were disrupting systems previously set up via the international health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing scheme created to deal with potential pandemics.
"This framework is designed to guarantee that when a country contributes its data, the benefits – such as medicines and cures – are distributed fairly, not monopolised exclusively by those with the funds to create them."
These objections regarding the US deal "must not be interpreted as opposition to America," he added.
"We welcome ongoing discussions with our American counterparts on how subsequent co-operation might be arranged in a way that respects the sovereignty and dignity of both nations."
Medical Community Response
Medical experts expressed it recognised the official position, but suggested that negotiations must proceed since a large portion of the nation's HIV programmes depended on external financing.
"Where specific concerns exist, such as those involving data governance or implementation frameworks, these can frequently be resolved via technical clarification and negotiated safeguards," the group added.
This impasse highlights the continuing debate between receiving vital foreign assistance and protecting national sovereignty in an ever more data-driven world.